Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204203 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
A Phase 2 study of Mesothelioma, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT01204203: Completed Phase 2 study of Mesothelioma, sponsored by University of Alabama at Birmingham.
NCT01204203 is a Phase 2 study of Mesothelioma that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 8 participants, below the 198-participant average among 46 other Mesothelioma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01204203, a Phase 2 study of Mesothelioma, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this trial is to determine the response rate of single agent zoledronic acid using a composite of criteria including the EORTC modified RECIST criteria and the EORTC tumor response criteria for 18F-FDG PET scans.
Primary Outcome
The modified Response Evaluation Criteria in Solid Tumors Criteria (RECIST 2004) will be used for target lesions and assessed by CT scans. Complete Response (CR) is the disappearance of target lesions; Partial Response (PR) is greater than or equal to 30% reduction in the total tumor measurement; Stable Disease (SD) is the absence of response or progression; and Progressive Disease (PD) is a 20% increase in the total tumor measurement over nadir value or the appearance of new lesions.
Conditions Studied
Interventions
- DRUG Zometa
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-06 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
What the finished NCT01204203 record still lists
NCT01204203 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 198-participant average among 46 other Mesothelioma trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Mesothelioma appearing as the primary indexed condition, and to 1 intervention - of which Zometa is the first listed.
NCT01204203 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT01204203 about?
NCT01204203 is a clinical study titled "Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)". The primary objective of this trial is to determine the response rate of single agent zoledronic acid using a composite of criteria including the EORTC modified RECIST criteria and the EORTC tumor response criteria for 18F-FDG PET scans.
What is the current status of trial NCT01204203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2009-06. Estimated completion is 2016-04.
What conditions does trial NCT01204203 study?
This clinical trial studies the following conditions: Mesothelioma.
What interventions are being tested in trial NCT01204203?
The interventions under investigation include: Zometa (DRUG).
Who is sponsoring clinical trial NCT01204203?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01204203 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01204203's enrollment target sits among peer trials
8 45th of 46 higher than 2 of 46 other Mesothelioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mesothelioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Olaparib in Patients With HRD Malignant Mesothelioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
RECRUITING · Phase 2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RECRUITING · Phase 2
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia